NCT02721069View on ClinicalTrials.gov

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

April 11, 2016

Primary Completion Date

June 17, 2020

Study Completion Date

July 23, 2020

Conditions
Acute Repetitive SeizuresBreakthrough Seizures
Interventions
DRUG

NRL-1

Trial Locations (5)

10016

New York University Comprehensive Epilepsy Center, New York

19107

Thomas Jefferson University Hospital Laboratory, Philadelphia

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

72205

Clinical Trials, Inc., Little Rock

Sponsors

Lead Sponsor

Neurelis, Inc.
All Listed Sponsors
lead

Neurelis, Inc.

INDUSTRY

NCT02721069 - Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects | Biotech Hunter | Biotech Hunter